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Original Article
Abstract
Purpose: The primary purpose of this study is to introduce fluorescence spectroscopy technology as a tool for optical biopsy and
to evaluate the reliability of this real-time non-invasive technique in assessing tumor therapeutic response in radiotherapy.
Methods: Four oral cancer patients with inflammatory conditions of the oral cavity volunteered to participate in the study. Us-
ing FastEEM (Excited Emission Matrix), spectra were taken from both normal and tumor regions. Then the second optical di-
agnostic was taken from the tumor regions in 4 patients with time delay of 4 weeks. The fluorescence spectroscopy optical bi-
opsy turned out to be more suitable for tumor diagnostics as there was a significant difference in fluorescence spectra. Results:
The first fluorescence intensity of cancerous tissue was higher compared to the second fluorescence intensity of optical biopsy
of cancerous oral tissue. From this result, it can be concluded that the fluorescence spectroscopy optical biopsy, which is a tech-
nique that does not require removal of tissue sample from body, is a reliable tool to be used in radiotherapy. Conclusion:
FastEEM, which is a tool for fluorescence spectroscopy, enables a real-time non-invasive assessment of the chemical, biological,
as well as morphological variations in the tissue composition following radiotherapy.
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Introduction
The outcomes of cancer treatments such as radiotherapy,
photodynamics therapy, chemotherapy, and gene-therapy
depend on factors like tumor type, tumor stage, and patient
health. For advanced-stage tumors, neoadjuvant therapies
such as chemotherapy, radiation therapy, and combination
therapy (i.e. chemo-radiation therapy) are often used to de-
crease tumor size before surgery. Since those therapies are
often used before conducting surgeries, tumor resection and
organ preservation are feasible. Sometimes patients gain
complete recovery from neoadjuvant therapies. On the other
hand, some patients do not exhibit favorable responses to
such treatment. These varied responses result from differ-
ences in tumor functional parameters across the patient pool.
The effectiveness of cancer treatment is judged mainly by
the extent of reduction in tumor size. However, tumor func-
tional changes (e.g. changes in tumor metabolism) from
treatment often precede gross structural changes. Thus
methods sensitive to tumor functional changes are of interest
for assessing treatment efficacy early and for adjusting the
treatment plan accordingly.1, 2
Optical spectroscopic diagnostics allow non-invasive physi-
cal and chemical characterization of biological tissues.3, 4 The
structural and chemical composition of cells and tissues
strongly influence their optical features, and therefore, al-
terations in the optical characteristics may indicate the
presence of diseased tissue. Optical spectroscopy may pro-
vide possibilities in the early detection of cancerous tissues
in humans. Biochemical and structural or morphological
information can be gained by measuring absorption, (auto)
fluorescence, elastic scattering, or Raman scattering. These
spectroscopic techniques have distinct physical bases and
each have the potential to become a more advanced conven-
tional cancer detection method when combined to form an
adjuvant method.3-5 Nonetheless, of all these optical tech-
niques, spectroscopy of tissue auto-fluorescence has been
considered to be the most promising.
Laser-induced fluorescence (LIF) is a real-time spectroscopic
technique that can be used to characterize biomedical and
morphological changes of different kinds of tissue both in
vitro6 and non-invasively in vivo. In vitro fluorescence
measurements are usually recorded from an area of the tissue
surface that is larger than the size of the excitation beam.
Most clinical applications of fluorescence spectroscopy re-
quire that spectra be recorded remotely via optical fibers.
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The fluorescence is therefore collected from a relatively
smaller area of the tissue surface.7, 8 The sampling depth for
fluorescence measurement is determined by the penetration
depth of the excitation light, the various fluorescence coeffi-
cients of the tissue layers, the escape functions for the fluo-
rescence, as well as the detection geometry.8
It is often the shape of the fluorescence spectra, and not the
fluorescence intensity, that is used for diagnostic purposes.
The difference in excitation and/or emission spectra between
normal and malignant tissues can thus be an important tool
for tissue diagnostics. This makes the measurement slightly
less dependent on the detection geometry, the exact excita-
tion power, and the detector sensitivity.
Fluorescence that is obtained from endogenous tissue fluor-
ophores without any external fluorophore added is called
autofluorescence.9 Alterations in tissue composition from
normal to malignant tissue form a basis for the diagnostic
potential for demarcating neoplastic tissue.10 Tissue fluoro-
phores will normally fluoresce in the visible wavelength
range following excitation with radiation in the UV and
near-UV region. The auotofluorescence intensity is fre-
quently lower in tumor tissues compared to that in the sur-
rounding normal tissues.11, 12 The endogenous tissue fluoro-
pores can be divided into two main groups; one group in-
volved in the cellular energy metabolism and the other in
the structural proteins.3 The most important tissue fluoro-
phores are collagen, elastin, and NADH (Nicotinamide ade-
nine dinucleotide)/NADPH (Nicotinamide adenine dinucle-
otide phosphate).13, 14 All fluorescence spectra recorded from
the tissues are also influenced by the optical properties of the
tissues. This means that those absorbers do not fluoresce, but
still absorb either the excitation or fluorescent light, ulti-
mately affecting the overall intensity of the fluorescence
spectra. The shape of the spectra is usually less affected as
the absorption coefficient in the visible region is lower than
that of the excitation light in the violet or near-UV region.14
Figure 1 shows the fluorescence emission spectra of tissue
fluorophores after being excited with 337 nm light. It com-
pares the fluorescence spectra obtained from a pre-malignant
lesion and the normal surrounding tissue in vivo after ad-
ministration of ALA (Aminolevuliniv acid). The wavelength
of the excitation light was 405 nm and the dual emission
peaks from PpIX (Protoporphyrin IX) were obtained at 635
nm and 705 nm.
Ionizing radiation in radiotherapy causes atoms and mole-
cules in tissues to become ionized or excited. This can ulti-
mately produce free radicals, break chemical bonds, form
new chemical bonds and cross-linkage between macromole-
cules, or damage molecules that regulate vital cell processes
(e.g. DNA, RNA, proteins). In cases of intensive radiation,
cells would not be replaced fast enough and tissues will fail
to function.
FIG. 1: Fluorescence spectra; (a) from some important tissue
fluorophores following  337 nm excitation, (b) typical average
fluorescence spectra obtained in vivo from normal and premalignant
lesion on vocal folds, using 405 nm excitation light where ALA has
been applied prior to the examination. Modified from Ref (Eker C).4
To better understand the clinical responses of tumors to ra-
diation therapy, experiments need to shift from individual
cell to tissue level. This understanding will in turn allow the
application of clinical knowledge to cancer treatment to
monitor therapies. In clinical radiation therapy, the dose of
radiation that can be applied is limited, because of its damage
on the surrounding normal tissues. The efficacy of the ther-
apy can be improved both through more efficient radiation
delivery to the tumor with minimization of normal tissue
damage and through increased sensitivity of the tumor to
radiation. First, effective radiation delivery to the tumor is
achieved by better X- and γ-ray treatment machines. They
use a better arrangement of source distribution so that even
deep human tumors (compared to those at the surface) can
be treated effectively without too much normal tissue dam-
age. To increase the sensitivity of the tumor, however, one
first needs to understand the difference in biological re-
sponses of tumors and normal tissues. The deployment of
fractionated radiation, which involves 1-2 Gy dosage a day
over a total of 5 to 7 weeks, is one of the most important
developments in this respect. During fractionation, dosage
can be adjusted based on the tumor response as it is done
during accelerated radiation therapy. Furthermore, increas-
ing oxygen sensitivity and modulating the vascular response
can lead to improved treatment efficacy.
Methods and Materials
Patients
Four volunteer oral cancer patients with a known or sus-
pected premalignant or malignant oral cavity lesion were
recruited from the Department of Oral Cancer Center at the
Medical School, University of Hallym. Informed consent was
obtained from each person.
Instrument
An instrument for acquisition and analysis of tissue fluores-
cence in a clinical setting must meet several requirements.
Since native tissue fluorescence (auto fluorescence) is weak,
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sensitive detection and strong excitation are required. Data
acquisition must provide a good S/N ratio, but it should also
be rapid enough to avoid motion artifacts and not interfere
with the routine clinical procedure. In addition, a wide range
of fluorescence excitation wavelength must be available in
order to provide complete information about the optical
properties of the tissue sample. Furthermore, the components
must be able to be interfaced with rapid on-line data analysis
software. Finally, the system must require little maintenance,
be portable, be easy to use, and be compact. These design
issues were key factors taken into account when designing
FastEEM.
The spectroscopic system used to measure fluorescence EEMs
shown in Figure 2 measures fluorescence emission spectra at
11 excitation wavelengths, within the range of 308 to 505 nm.
The system incorporates a fiber-optic probe and two kinds of
light sources; dye laser pumped by a nitrogen laser (337 nm,
model VSL-337MD; Laser Science, Inc) laser and a xenon arc
lamp (EG&G Optoelectronics, FX-139). The dye laser con-
sists of ten cuvettes that are mounted on a wheel driven by a
motor rotating at 5 Hz. The fluorescence spectra of the dye
laser used ranged from 350 nm to 650 nm and the emission
power correlated with the wavelength of the dye. The power
was always less than 20µJ. The xenon arc lamp is for white
light reflectance spectrum from 300 to 800 nm and is coupled
with a monochromator to provide excitation light. It is also
connected to a cooled Intensity charge-coupled device
(ICCD) camera (Max 1024; EG&G Instruments Princeton
Applied Research) that records fluorescence intensity as a
function of emission wavelength. Fluorescence emission as
well as reflectance signals were collected by the fiber-optic
probe consisting of seven multimode optical fibers with di-
ameters of 1.5 mm. They were coupled to a scanning imaging
spectrograph (CP 200, Jobin Yvon SA, Edison, NJ) fitted with
a high-sensitivity ICCD array. The EEM collection time was
optimized in less than 1 second through the ICCD-fitted
spectrograph with multiple emission intensities being read
simultaneously. The excitation wavelength range was ex-
tended to 308-505 nm and emission was collected between
the wavelengths of 300 and 700 nm.
FIG. 2: (a) Schematic with excimer laser and flash lamp
FIG. 2: (b) Photograph of FastEEM.
Calibration
Thorough calibration of the system was performed prior to
data collection. A mercury lamp was used to calibrate the
wavelength scale of the ICCD detector. A NIST standard
tungsten lamp provided spectral response calibration (pri-
marily determined by the spectrograph grating and ICCD
detector). A spectralon disk (Labsphere) with approximately
20% reflectance was used for white light reflectance calibra-
tion to correct for the xenon flash lamp spectral line shape
and intensity. Fluorescence intensity correction was achieved
using a cuvette with a standardized solution of rhodamine B
in thylene glycol. This allowed for a comparison of tissue
fluorescence intensities without day-to-day intensity fluctu-
ations that result from small variations in system alignment.
Furthermore, by measuring the Rhoda mine fluorescence
response on a well calibrated spectrofluorimeter at different
excitation wavelengths, FastEEM system was calibrated to
account for variations in laser power at different excitation
wavelengths.
Finally, a background spectrum for all excitation wavelengths
was recorded and was subtracted from the patient data to
eliminate the offset resulting from dark counts of the ICCD
detector and fluorescence and reflectance background created
by the optical fiber probe.
The spectralon, Rhodamine, and background calibration data
were stored in the system and were used for automatic cali-
bration and display of the data. Additionally, these files were
used in data processing to obtain an on-line diagnosis. Several
concentrations of different fluorophores were measured to
determine the sensitivity and response of the system over a
large wavelength range.
Measurement
CT (Computed Tomography) and MRI (Magnetic resonance
imaging) scans provided additional information about the
location and size of each tumor. FastEEM measurements were
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carried out consecutively. The pre-radiation measurements
were used as baseline data. Subsequently, weekly measure-
ments were carried out for each individual until the treat-
ment was completed. Each patient received daily fractionated
irradiation from Monday through Friday, and the optical
fluorescence spectroscopic measurements were completed
just before treatment began each week. Daily fractionated
radiotherapy was administrated with a 3D conformal radio-
therapy technique. A simultaneous in-field boost prescription
technique was used for prescribing 50 Gy in 2.5 Gy per frac-
tion over 20 fractions for both primary and gross neck disease.
The duration of treatment was about 4 weeks. The standard
RECIST (Response Evaluation Criteria In Solid Tumors) was
applied to classify tumor responses.15 A responder is defined
as a patient with no evidence of residual cancer in the neck
dissection specimen at the end of treatment. Formal assess-
ment of treatment response was conducted 4 weeks after
completing the therapy. Post-radiotherapy neck dissections
were evaluated using a pathologic response.
Data analysis
In this part of the study, software was developed to perform
data analysis in real time. Fluorescence and reflectance spec-
tra have been analyzed using extensive modeling of
light-tissue interactions to provide three types of spectro-
scopic information; Intrinsic Fluorescence Spectroscopy
(IFS), Diffuse Feflectance Spectroscopy (DRS), and Light
Scattering Spectroscopy (LSS).16-18 In the IFS analysis, infor-
mation from measured fluorescence and reflectance spectra
were combined using a photon migration-based model. The
model was used to extract the intrinsic tissue fluorescence
that is free from distortions introduced by tissue scattering
and absorption. Intrinsic tissue fluorescence spectra were
then decomposed into a linear combination of fluorescence
contributions from collagen and NADH, or other diagnosti-
cally important chromosphores.5 Thus we extracted quanti-
tative biochemical information that can be compared to a
specific pre-determined threshold to classify the examined
tissue site as normal or diseased. The measured reflectance
spectra were processed using DRS and LSS analysis to obtain
information from multiply and singly backscattered light.
In the LSS step, the spectral features of the multiply scat-
tered light determined by the diffusion model analysis were
subtracted from the measured reflectance. This provided the
spectrum of light that is backscattered from the tissue after
undergoing a single scattering event. Analysis of this spec-
trum yielded information about the size distribution and
number density of the nuclei of epithelial cells. The values of
these parameters were compared to pre-established thresh-
old values to determine whether the light scattering charac-
teristics of the examined tissue sites are consistent with
normal or diseased tissue. In the final step of the analysis,
information from the IFS, DRS, and LSS analyses were com-
bined to form a consensus diagnosis.5 This appears in the
LABVIEW operator control window. The entire data analy-
sis process took 10 seconds using an Intel Celeron processor,
but can be expected to be significantly faster (3 seconds)
when a faster computer is used.
Results
In this experiment, we tried to obtain two types of data to
monitor tumor radiotherapy. The first was the response of the
blood and the other was the spectrum analysis in the fluo-
rescence spectroscopy.
TABLE 1: Characteristics of patients with oral cancer (SCC = squa-
mous cell carcinoma, TNM = Tumor, Node, Metastasis stage
Patient Age/Sex Histologic TNM Size/Depth Treatment
No Type stage (cm) response
P-1 58/F SCC T4N2bM0 4.1×2/0.4 complete
P-2 61/M SCC T2N2bM0 2.1×2.4/0.3 complete
P-3 50/M SCC T4N2cM0 3.6×3.1/0.5 complete
P-4 63/M SCC T2N2cM0 3.3×2.8/0.3 complete
TABLE 2: Individual tumor (t) and normal tissue (n) relative blood
flow changes (rBF(%)) at the end of week-1, week-2, week-3 and
week-4 of radiotherapy. Pretreatment value at week-0 was defined as
100% in all patients.
Patient Tissue Week-1 Week-2 Week-3 Week-4
No type (%) (%) (%) (%)
P-1 t 150 ± 4 126± 3 92 ± 2 113 ± 6
P-1 n 101 ± 6 112 ± 4 103 ± 4 113 ± 5
P-2 t 162 ± 7 152 ± 4 167 ± 2 123 ± 7
P-2 n 93 ± 4 98 ± 6 89 ± 3 101 ± 1
P-3 t 114 ± 7 132 ± 4 144 ± 1 119 ± 12
P-3 n 85 ± 2 89 ± 8 95 ± 4 92 ± 7
P-4 t 156 ± 4 136 ± 1 114 ±6 166 ± 3
P-4 n 107 ± 1 99 ± 4 87 ± 2 82 ± 9
TABLE 3: Weekly blood oxygen saturation (StO2) (%) changes dur-
ing radiotherapy for both tumor (t) and normal tissue (n).
Patient Tissue Week-0 Week-2 Week-3 Week-4 Week-4
No type (%) (%) (%) (%) (%)
P-1 t 54 ± 4 51± 3 52 ± 2 48 ± 6 48 ± 4
P-1 n 56 ± 5 52 ± 4 57 ± 4 53 ± 2 52 ± 6
P-2 t 62 ± 7 58 ± 4 57 ± 3 63 ± 7 61 ± 7
P-2 n 53 ± 4 61 ± 2 60 ± 3 67± 1 64 ± 4
P-3 t 64 ± 1 62 ±7 66 ± 1 59 ± 12 61 ± 4
P-3 n 68 ± 2 63 ± 8 71 ± 4 67 ± 7 66 ± 2
P-4 t 63 ± 4 66 ± 1 64 ±6 73 ± 3 69 ± 4
P-4 n 67 ± 1 75 ± 4 69 ± 2 77 ± 9 73 ± 1
A total of 4 oral cancer patients were examined weekly. The
patient and tumor characteristics are given in Table 1. Tables
2 to 4 summarize the data from tumor (t) and normal tissue
(n) of 4 patients. Table 2 exhibits rBF (relative Blood Flow)
[%] at the end of week-1, week-2, week-3 and week-4 of
radiation therapy. The pre-treatment value at week-0 was
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defined as 100% in all patients. Similarly, Table 3 and Table 4
summarize weekly changes of StO2 (oxygen saturation) [%]
and THC (total hemoglobin concentration) [¹M], respective-
ly. This has also been the case in animal experiments and
clinical trials that employed radiation therapy; apparently
this variation is only partly a result of methodological factors
such as differences in probe handling and positioning on the
tissue.1, 19
TABLE 4: Weekly total hemoglobin concentration (THC) (¹M)
changes during chemoradiation therapy for both tumor (t) and
normal tissue (n).
Patient Tissue Week-0 Week-2 Week-3 Week-4 Week-4
No type (mM) (mM) (mM) (mM) (mM)
P-1 t 84 ± 4 71± 3 72 ± 2 68 ± 6 58 ± 4
P-1 n 76 ± 2 69 ± 7 75 ± 3 69 ± 2 63 ± 6
P-2 t 72 ± 7 68 ± 3 77 ± 1 73 ± 6 71 ± 9
P-2 n 73 ± 8 75 ± 2 80 ± 1 77± 9 84 ± 2
P-3 t 64 ± 1 62 ±7 66 ± 1 59 ± 12 61 ± 4
P-3 n 78 ± 2 83 ± 2 81 ±2 87 ± 1 86 ± 2
P-4 t 53 ± 4 46 ±9 51 ±6 49 ± 3 55 ± 4
P-4 n 61 ± 1 55 ± 2 62 ± 7 57 ± 9 66 ± 5
The biological significance of an increase in tumor blood flow
is not well understood. It is possible that the increase may
improve tumor oxygenation, which in turn might improve
tumor radiosensitivity.20 The mechanism for such a favorable
response might be reflected in the observations of Sonveaux.2
These investigators concluded that clinically relevant doses of
radiation elicit a vascular stress response with increased se-
cretion of tumor endothelial nitric oxide. This in turn can
cause vasodilation, increased blood flow and vessel permea-
bility. Alternatively, this early increase in blood flow may
reflect a corresponding decrease in the interstitial fluid
pressure, which affects the tumor vessel consequentially, the
blood flow.21 Preferential damage to a sub-population of
oxygenated cells may lower the interstitial pressure on micro
vessels within the tumor, thus opening capillaries and in-
creasing tumor blood microcirculation.22 This effect can fa-
cilitate improved chemotherapy delivery to tumors as has
been demonstrated in pre-clinical xenograft models.23
Figures 3 and 4 show relative intrinsic fluorescence spectra
of adenomatous oral tissue and of 4 normal tissue sites. The
data was obtained by using the measured fluorescence and
reflectance and the values were inserted into Equation 1 in
order to extract the intrinsic fluorescence. The four polyps



























Equation (1) establishes a relationship between the intrinsic
fluorescence spectrum, fxm, the experimentally measured
fluorescence spectrum, Fxm, and the diffuse reflectance spec-
trum, Rm. This equation was derived to show that fluores-
cence can be treated in a similar way as the reflectance. For a
fluorescence measurement on a sample with the same
amount of fluorophore without absorbers and scatters, the
intrinsic fluorescence spectrum, fxm, can be obtained.
FIG. 3: Fluorescence spectrum of normalized intrinsic fluorescence
spectra of 4 adenomatous tissues and 4 normal tissues in oral site
FIG. 4: (a) Fluorescence spectrum of Oral cavity tissue before radio-
therapy (4 upper spectrum show the normal tissue, 4 lower spectrum
show the cancerous tissue)
b
FIG. 4: (b) Fluorescence spectrum of Oral cavity tissue after radio-
therapy (4 weeks) (the 4 lines represent the spectra before radio-
therapy and the dashed lines show the results after radiotherapy).
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In Figure 4 (a), Optical fluorescence spectrums showed the
possibility of detection of oral cancer as an optical diagnos-
tics tool before radiotherapy treatment. The 4 fluorescence
spectra of normal tissue form a line that is above the other 4
spectra that represent the oral cancer tissue. It shows that
the fluorescence intensity of cancer tissues is higher than
that of the normal tissue. Figure 4 (b) shows the variation of
fluorescence spectrum after radiotherapy in 4 patients. All 4
patients who had treatment by radiation for 5 weeks are
measured by FastEEM. All fluorescence spectrums intensity
after radiotherapy decreased down to the lower after radio-
therapy.
Discussion
In this study, we have demonstrated the feasibility of optical
fluorescence spectroscopy as an optical biopsy tool for mon-
itoring oral cancer patients in radiation therapy. First, this
was done by using a standard spectrofluorimeter to measure
fluorescence EEMs and to determine the location of the en-
dogenous fluorescent peaks and their relative intensity in
normal and adenomatous oral tissues for diagnostic in vivo.
Next, fluorescence spectra were measured to examine the
variations in cancer tissues after radiotherapy. We observed
significant differences between the autofluorescence spectra
of normal tissues and adenomatous oral tissues.
These differences could be attributed to the differences in
fluorophores expression. The endogenous fluorophores that
are speculated to be the indicators of cancerous transfor-
mations are the amino acids tryptophan and tyrosine, the
structural proteins collagen and elastin, the coenzymes NAD
(P)H and FAD (Flavin adenine dinucleotide), and phorphy-
rins. When normal and diseased tissues were compared, the
concentration of NADH was higher and the fluorescence
intensity was lower in cancerous tissues. This was because
the polyp present in abnormal skin made the epidermal layer
thicker. However, the second graph of Figure 4 depicts the
same portion of cancerous skin before and after treatment.
Since the depth of the layer is the same, the fluorescence
decreases upon treatment as the NADH level is reduced.
There were some limitations with the current approach and
gap for future improvement. In this study, different observ-
ers could have possibly applied different probe-tissue pres-
sure and introduced different probe positioning. These ef-
fects could have induced variations in quantification, which
were quantified and reported as error bars in the figures. In
addition, the human oral region consists of different ana-
tomical tissues such as muscle and fat, with its proportion
varying across patients. Thus the semi-infinite homogeneous
medium approximation is unlikely to be exactly valid. Nev-
ertheless, we have confined to employing the semi-infinite
approximation, because it enabled a simplification of analysis
and the extraction of trends from the weekly measurements.
Better quantification, as well as increased ability to distin-
guish different tissue structure (tumor, normal tissue) can be
obtained from similar measurements using larger numbers of
sources and detectors, and also by image segmentation based
on other available anatomical information.24
However, in practice, a larger number of sources and detec-
tors also introduces some difficulty interfacing the probe to
the tissue. From experience, we have found that the rela-
tively large probe having many fibers was disadvantageous
when trying to contact all fibers to the tissue surface with
equal pressure. Therefore, a bulkier single probe containing
numerous blood flow and oxygen saturation fibers was
avoided. In the future a better probe design may enable a
better quantification that preserves good probe tissue con-
tact.
Finally, limitations such as uncertainties in tumor bounda-
ries can potentially be eliminated by comparing the optical
fluorescence spectroscopy diagnostic methods with other
structural imaging modalities such as ultrasound and MRI.
Since CT is available only before therapy, adding a structural
imaging methodology such as ultrasound to our protocol
would enable us to assess tumor size changes weekly during
therapy. Tissue heterogeneity effects may also be investigat-
ed with imaging techniques.
In this study we have primarily focused on the changes of
fluorescence spectrum responses of the tumor that result
from radiation therapy. Since the assessment of early re-
sponse could potentially improve treatment outcome, the
results we have presented encourage one to focus on early
weeks. Our results suggest that early clinical tumor response
to radiation therapy can be detected and quantified by opti-
cal fluorescence spectroscopy. The data clearly start to ex-
hibit significant changes within 14 days of therapy. The ear-
ly flow changes may be significant in affecting drug delivery
efficacy and/or tumor oxygenation during radiation therapy
and the early tumor oxygenation changes may be related to
tumor response. The responses of 4 oral patients were similar
to each other, but were different from those of the partial
responder. Nevertheless, our statistics are not sufficient to
draw significant physiological conclusions. Since a primary
aim of therapy diagnostics is to predict the response as early
as possible, the early blood flow and oxygenation changes
observed here suggest the potential utility of daily measure-
ments during the 14 days of treatment. Since the detection of
differences between tumor and normal tissue in vivo, most
of optical diagnostics methods have advantage in the field of
early cancer detection and for daily based cancer therapy
including monitoring of the outcomes of radiotherapy.
Conclusion
Medical imaging techniques such as MRI, CT and PET are
being used as monitoring tools in tumor therapies (radio-
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therapy, chemotherapy, and gene-therapy). However, some
limitations include high measurement costs and time con-
sumption. Hence most oncologists may not be able to moni-
tor the effect or variation of tumor and normal tissues sur-
rounding the tumor during therapy.
This study demonstrates the applicability of fluorescence
spectroscopy in the monitoring tumor radiotherapy of oral
cancer. It was proven that the fluorescence spectroscopic
diagnostic technique can detect the difference between
premalignant lesion and squamous cell carcinoma of oral
cavity by measuring the fluorescence intensity variation in
fluorophore NADH in tissue after radiotherapy.
We have quantified tumor changes non-invasively during
radiotherapy using the optical fluorescence spectroscopy
with FastEEM. These techniques do not require contrast
agent administration and are suitable for bedside examina-
tions with rapid data acquisition. Our preliminary data
showed that patients exhibit significant changes in rBF, SO2,
THC and fluorescence spectrum even in the 4 week course of
the treatment. In one patient, a different trend was observed
with a preliminary indication that it coincided with a dif-
ferent treatment outcome. This odd observation should be
further studied with better statistics. At this point, it is diffi-
cult to determine what prognostic role these techniques will
play in the future. More statistical data are required for as-
sessment of the prognostic value of these optical diagnostics
technology. However, it can be expected that the fluores-
cence spectroscopy as one of optical diagnostics will be a
useful tool in monitoring tumor treatment in radiotherapy.
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